Is it a case for chemoablation?

These potential JELMYTO candidates present with a range of characteristics and histories.

Ted, 55

Newly diagnosed, primary disease

Sidney, 71

Recurrent, endoscopically managed

Mia, 76

Recurrent, comorbidities

Jonathan, 67

Bilateral disease
Profile photo of fictional patient named Ted

Does RNU have to be the next step for Ted’s unresectable primary disease?

Not an actual patient.

Ted, 55 years old, reported hematuria and flank pain. Urinalysis ruled out urinary tract infection. Cytoscopy ruled out bladder cancer.

Retrograde urography showed a large filling defect, and CT scan showed 2 endoscopically unresectable papillary tumors in the lower pole of the left renal pelvis. Ureteropyeloscopy and biopsy confirmed low-grade UTUC.

Father of 2 school-aged children, Ted is scared to lose a kidney. He prefers a noninvasive procedure that will not require extensive recovery.

    Key treatment considerations:
  • 2 kidneys
  • 2 unresectable papillary tumors
  • Diameter of largest tumor: 15 mm
  • Comorbidities: Hypertension
  • Treatment site: ASC
Jelmyto stays in the hard-to-reach areas of the renal pelvis for 4 to 6 hours, long enough to chemoablate Ted’s unresectable tumors.1See how Jelmyto rises to the challenge of the renal anatomy
Explore more of Ted’s case study and what Jelmyto can do for patients like him.Download PDF
ASC=ambulatory surgery center; CT=computerized tomography; RNU=radical nephroureterectomy.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UroGen Pharma at 1-855-987-6436.

Please click here for JELMYTO Full Prescribing Information, including the Patient Information, for additional information.

Please click here for Full Prescribing Information, Instructions for Pharmacy, and Instructions for Administration.